Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
ESMO Open
|
November 3, 2022
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials
E Dell'Aquila, D Rossini, C A M Fulgenzi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 30, 2025
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies
R Moretto, D Rossini, Mariam Grazia Polito, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study
C Cremolini, F Morano, R Moretto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO
M M Germani, V Heinemann, D Rossini, et al.
Cancer Medicine
|
March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
G Martini, D Ciardiello, V Famiglietti, et al.
ESMO Open
|
June 13, 2022
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
A Boccaccino, B Borelli, R Intini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2016
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
F Pietrantonio, R Miceli, L Rimassa, et al.
ESMO Open
|
July 16, 2025
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset
V Daprà, A Gandini, F Schietroma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2019
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies
F Marmorino, D Rossini, S Lonardi, et al.
ESMO Open
|
November 8, 2025
Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis
G Trovato, D Rossini, A Guidolin, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
ESMO Open
|
November 3, 2022
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials
E Dell'Aquila, D Rossini, C A M Fulgenzi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 30, 2025
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies
R Moretto, D Rossini, Mariam Grazia Polito, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study
C Cremolini, F Morano, R Moretto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO
M M Germani, V Heinemann, D Rossini, et al.
Cancer Medicine
|
March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
G Martini, D Ciardiello, V Famiglietti, et al.
ESMO Open
|
June 13, 2022
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
A Boccaccino, B Borelli, R Intini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2016
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
F Pietrantonio, R Miceli, L Rimassa, et al.
ESMO Open
|
July 16, 2025
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset
V Daprà, A Gandini, F Schietroma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2019
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies
F Marmorino, D Rossini, S Lonardi, et al.
ESMO Open
|
November 8, 2025
Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis
G Trovato, D Rossini, A Guidolin, et al.
Page
of 6